Sign in
CompletedPhase 4

Aspirin to prevent cardiovascular events in patients with pneumonia or influenza

Key facts

Who runs it
Amsterdam UMC
Where
Netherlands16 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 4
People taking part
760 people enrolled
Started
27 Dec 2023
Ended
30 Jun 2026
Type of study
Interventional
Record updated
9 October 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • 40 years or older
  • Any of the following respiratory infections: moderate to severe community-acquired pneumonia (defined as clinical signs of pneumonia, radiological evidence of a new infiltrate consistent with pneumonia, and severity score CURB-65 score ≥2 or PSI score ≥3) or influenza (defined as clinical signs of a respiratory infection and a positive influenza PCR test result)
  • Admitted to hospital

Who cannot take part

  • Conditions which require antiplatelet therapy
  • Contraindications for aspirin: recent (<1 month) hemorrhagic CVA, recent major gastro-intestinal bleeding or other hemorrhage, active bleeding, thrombocytopenia < 100, known hemorrhagic diathesis, allergy for salicylates
  • Uncontrolled hypertension (systolic BP>180 mm Hg or diastolic BP>110 mm Hg)
  • Use of vitamin K antagonists, direct oral anticoagulants or therapeutic LMWH
  • Life expectancy less than one month
  • Pregnancy or breastfeeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To investigate whether adding aspirin to standard therapy in patients with moderate to severe community-acquired pneumonia or influenza will reduce the incidence of acute coronary syndrome in hospitalized patients

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Aspirin to prevent cardiovascular events in patients with community-acquired pneumonia or influenza
Record updated
9 October 2025